Author

C. Gervais

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:wet-lab / biochemical assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:flow cytometry· 1

Frequent Co-Authors

M. Stuible· 2 shared S. Perret· 2 shared Y. Durocher· 2 shared A. Kaiser· 1 shared A. Kinkhabwala· 1 shared A. Lupo· 1 shared A. Tran· 1 shared A. Trautmann· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

M. Stuible

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Arsenal of Nanobodies for Broad-Spectrum Countermeasures against Current and Future SARS-CoV-2 Variants of Concerns

M. A. Rossotti, H. van Faassen, A. Tran, J. Sheff, J. A. Sandhu, D. Duque, M. Hewitt, S. Wen, R. Bavananthasivam, S. Beitari, K. Matte, G. Laroche, P. M. Giguere, C. Gervais, M. Stuible, , J. Tanha

This paper presents a diverse set of nanobodies targeting SARS-CoV-2 spike glycoprotein with broad neutralization activity against multiple variants and high in vivo efficacy.

bioRxiv · Dec 20, 2021 · PreprintBioengineering

Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells

M. Stuible, C. Gervais, S. Lord-Dufour, S. Perret, D. L'Abbe, J. Schrag, G. St-Laurent, Y. Durocher

The paper develops a method to rapidly produce high-yield, full-length SARS-CoV-2 spike protein using CHO cells and reports yields of 100-150 mg/L.

bioRxiv · Sep 8, 2020Bioengineering

CAR T cell entry into tumor islets is a two-step process dependent on IFNγ and ICAM-1

C. Kantari-Mimoun, S. Barrin, S. Haghiri, C. Gervais, J. Mittelstaet, N. Mockel-Tenbrinck, A. Kinkhabwala, D. Damotte, A. Lupo, M. Sibony, M. Alifano, L. Vimeux, E. Dondi, N. Bercovici, A. Trautmann, , E. Donnadieu

This study shows CAR T cell entry into tumor islets occurs in two steps, requiring IFNγ and ICAM-1 for effective infiltration.

bioRxiv · May 27, 2020Immunology